BUSINESS
Epclusa Hits Japan Market, 1st Drug for Hep C with Decompensated Cirrhosis
Gilead Sciences’ new hepatitis C drug Epclusa (sofosbuvir + velpatasvir) was launched in Japan on February 26 upon its NHI price listing the same day, making the first treatment option available for patients with decompensated cirrhosis. Epclusa encapsulates sofosbuvir, a…
To read the full story
Related Article
- Gilead Seeks Label Expansion for Epclusa in Japan
September 29, 2021
BUSINESS
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
- Fuji Poised to Hit 10 Billion Yen Biosimilar Sales Mark, Led by Eylea Follow-On
November 16, 2026
- Seikagaku Sees Over a Year Before US Refiling of Herniated Disk Drug
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





